Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have given written informed consent and be able to comply with all study requirements~* Healthy males or females aged 18-65 inclusive~* Females must be non-pregnant and non-lactating, and either surgically sterile or post- menopausal~* Males must be surgically sterile, abstinent or using an acceptable contraceptive method~* BMI \< 35.0 kg/m2~* Subjects must have Fasting TG ≥ 90 mg/dL or ≥ 200 mg/dL depending on Cohort assignment~Exclusion Criteria:~* Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B~* Treatment with another Study Drug, biological agent, or device within one-month of screening~* Regular excessive use of alcohol within 6 months of Screening~* Use of concomitant drugs unless authorized by the Sponsor Medical Monitor~* Smoking \> 10 cigarettes a day~* Considered unsuitable for inclusion by the Principal Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- IONIS-APOC-III-LRx (Type: EXPERIMENTAL): Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
- Placebo (Normal Saline) (Type: PLACEBO_COMPARATOR): Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).